Autres langues Zai Lab Limited Boerse Muenchen

Actions

1ZL

US98887Q1040

Produits pharmaceutiques

Marché Fermé - 22:44:01 29/09/2026 Varia. 5j. Varia. 1 janv.
22,80 EUR +0,88 % Graphique intraday de Zai Lab Limited -3,42 % +51,68 %

Autres langues

29/09 Zai Lab Limited To Present First Global Data From Clinical Trial Evaluating Zocilurtatug Pelitecan As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer
29/09 Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
24/09 Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
04/09 Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading
02/09 Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
31/08 Asian Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
28/08 Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up 2% for Week
26/08 Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%
25/08 Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
19/08 Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading
17/08 Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
17/08 Zai Lab Limited and Argenx Announces Positive Topline Results From Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis
13/08 Asian Equities Traded in the US as American Depositary Receipts Marginally Higher in Thursday Trading
11/08 Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
07/08 Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; End Week Up 2%
06/08 Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
06/08 Zai Lab Shares Rise After Q2 Beat
06/08 Zai Lab Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08 Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Revenue $106.3M, vs. FactSet Est of $103.9M
06/08 Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Loss of $0.46 per ADS, vs. FactSet Est of $-0.68
06/08 Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
03/08 Zai Lab Receives FDA Orphan Drug Designation for Zocilurtatug Pelitecan in Neuroendocrine Carcinomas
03/08 U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
29/07 Asian Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
22/07 Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
Aucun résultat pour cette recherche
🔇